相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumour markers in prostate cancer: The post-prostate-specific antigen era
Manuel M. Garrido et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2022)
Extracellular vesicles in prostate cancer: a narrative review
Koji Hatano et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke et al.
EUROPEAN UROLOGY (2020)
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Manish Kohli et al.
EBIOMEDICINE (2020)
The contribution of the 20th century discoveries on the circulating DNA as biomarkers for cancer screening
Gilda Alves et al.
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS (2020)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
Guru Sonpavde et al.
CANCER (2019)
Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer
H. Ballentine Carter et al.
EUROPEAN UROLOGY (2019)
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Gillian Vandekerkhove et al.
EUROPEAN UROLOGY (2019)
CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management
Santosh Shenoy
CANCER MANAGEMENT AND RESEARCH (2019)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Estrogen receptor (ESR1) mutation in bone metastases from breast cancer
Stephan Bartels et al.
MODERN PATHOLOGY (2018)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer
Benjamin L. Maughan et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
CDH1 Gene and Hereditary Diffuse Gastric Cancer Syndrome: Molecular and Histological Alterations and Implications for Diagnosis And Treatment
Wenyi Luo et al.
FRONTIERS IN PHARMACOLOGY (2018)
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na et al.
EUROPEAN UROLOGY (2017)
Liquid biopsy: a step forward towards precision medicine in urologic malignancies
Ashley Di Meo et al.
MOLECULAR CANCER (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
CDH1 germline mutations and hereditary lobular breast cancer
Giovanni Corso et al.
FAMILIAL CANCER (2016)
PSA and beyond: alternative prostate cancer biomarkers
Sharanjot Saini
CELLULAR ONCOLOGY (2016)
Regulation of the p53 response and its relationship to cancer
David W. Meek
BIOCHEMICAL JOURNAL (2015)
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
S. Salvi et al.
BRITISH JOURNAL OF CANCER (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer
Martina Kluth et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers
Min S. Kim et al.
APMIS (2013)
Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression
Ruth L. Vinall et al.
DISEASE MODELS & MECHANISMS (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
分享论文
